Expression of somatostatin receptor subtypes 1 to 5 in tumor tissue and intratumoral vessels in malignant endocrine pancreatic tumors

Medical Oncology

Volumn 20, Issue 1, 2003, Pages 59-67

  Fjällskog, Marie Louise ^a   Ludvigsen, Eva ^a   Stridsberg, Mats ^a   Öberg, Kjell ^a   Eriksson, Barbro ^a   Janson, Eva T ^a  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Endocrine pancreatic tumors; Immunohistochemistry; Intratumoral vessels; Somatostatin receptors

Indexed keywords

POLYCLONAL ANTIBODY; RECEPTOR SUBTYPE; SOMATOSTATIN RECEPTOR;

ADULT; AGED; ANTIBODY LABELING; ARTICLE; CANCER THERAPY; CONTROLLED STUDY; ENDOCRINE TUMOR; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; METASTASIS; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; QUANTITATIVE ANALYSIS; TISSUE DISTRIBUTION; TUMOR CELL; TUMOR DIFFERENTIATION; TUMOR VASCULARIZATION;

ADULT; AGED; BLOOD VESSELS; CARCINOMA, ISLET CELL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; LIVER NEOPLASMS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; RECEPTORS, SOMATOSTATIN;

EID: 0037233574     PISSN: 13570560     EISSN: None     Source Type: Journal    
DOI: 10.1385/MO:20:1:59     Document Type: Article

References (27)

1. Öberg K. Neuroendocrine gastrointestinal tumors - a condensed overview of diagnosis and treatment. Ann Oncol 1999; 10: S31-38.
2. Welbourn RB, Wood SM, Polak JM, Bloom SR. Pancreatic endocrine tumors. In: Bloom SR, Polak JR (eds). Gut Hormones. Churchill Livingstone, London, 1981, pp. 547-554.
3. Eriksson B, Öberg K. An update of medical treatment of malignant endocrine pancreatic tumors. Acta Oncol 1993; 32: 203-208.
4. Reubi JC, et al. Detection of somatostatin receptors in surgical and percutaneous needle biopsy samples of carcinoids and islet cell carcinomas. Cancer Res 1990; 50: 5969-5977.
5. Patel YC. Somatostatin and its receptor family. Front Neuroendocrinol 1999; 20: 157-198.
6. Scarpignato C. Somatostatin analogues in the management of endocrine tumors of the pancreas. In: Mignon M, Jensen RT (eds). Endocrine Tumors of the Pancreas. Karger, Basel, 1995, pp. 385-414.
7. Arnold R, et al. Somatostatin analogue octreotide and inhibition of tumor growth in metastatic endocrine gastroenteropancreatic tumors. Gut 1996; 38: 430-438.
8. Reubi JC, Horisberger U, Laissue J. High density of somatostatin receptors in veins surrounding human cancer tissue: Role in tumor-host interaction? Int J Cancer 1994; 56: 681-688.
9. Watson JC, et al. Growing vascular endothelial cells express somatostatin receptor subtype 2 receptors. Br J Cancer 2001; 85: 266-272.
10. Albini A, et al. Somatostatin controls Kaposi's sarcoma tumor growth through inhibition of angiogenesis. FASEB J 1999; 13: 647-655.
11. Yamada Y, et al. Cloning and functional characterization of a family of human and mouse somatostatin receptors expressed in brain, gastrointestinal tract and kidney. Proc Natl Acad Sci USA 1992; 89: 251-255.
12. Yamada Y, et al. Somatostatin receptors, an expanding gene family: cloning and functional characterization of human sstR3, a protein coupled to adenylyl cyclase. Mol Endocrinol 1992; 6: 2136-2142.
13. Yamada Y, et al. Cloning, functional expression and pharmacological characterization of a fourth (hsstR4) and a fifth (hsstR5) human somatostatin receptor subtype. Biochem Biophys Res Commun 1993; 95: 844-852.
14. Portela-Gomes GM, Stridsberg M, Grimelius L, Öberg K, Janson ET. Expression of the five different somatostatin receptor subtypes in endocrine cells of the pancreas. Appl Immunohistochem Mol Morph 2000; 8: 126-132.
15. Kulacsiz H, et al. Identification of somatostatin receptor subtypes 1, 2A, 3 and 5 in neuroendocrine tumors with subtype specific antibodies. Gut 2002; 50: 52-60.
16. Papotti M, et al. Expression of somatostatin receptor subtypes 1-5 in 81 cases of gastrointestinal and pancreatic endocrine tumors. A correlative immunohistochemical and reverse-transcriptase polymerase chain reaction analysis. Wirchows Arch 2002; 440: 461-475.
17. Rindi G, Capella C, Solcia C. Cell biology, clinicopathological profile, and classification of gastro-enteropancreatic endocine tumors. J Mol Med 1998; 76: 413-420.
18. O'Shaughnessy DJ. Radioimmunoassay of gut regulatory peptides. In: Bloom SR, Long RD (eds). Antibodies. WB Saunders, London, 1982, pp. 9-20.
19. Vaitukaitis J, Robbins JB, Nieschlag E, Ross GT. A method for producing specific antisera with small doses of immunogen. J Clin Endocrinol 1971; 33: 988-991.
20. Janson ET, Gobl A, Kälkner KM, Öberg K. A comparison between the efficacy of somatostatin receptor scintigraphy and that of in situ hybridization for somatostatin receptor subtype 2 messenger RNA to predict therapeutic outcome in carcinoid patients. Cancer Res 1996; 56: 2561-2565.
21. Buscail L, et al. Stimulation of tyrosine phosphatase and inhibition of cell proliferation by somatostatin analogues: mediation by human somatostatin receptor subtypes sstR1 and sstR2. Proc Natl Acad Sci USA 1994; 91: 2315-2319.
22. Buscail L, et al. Inhibition of cell proliferation by the somatostatin analogue RC-160 is mediated by somatostatin receptor subtypes sstR2 and sstR5 through different mechanisms. Proc Natl Acad Sci USA 1995; 92: 1580-1584.
23. Sharma K, Patel YC, Srikant CB. Subtype-selective induction of wild-type p53 and apoptosis, but not cell cycle arrest, by human somatostatin receptor subtype 3. Mol Endocrinol 1996; 10: 1688-1696.
24. Sharma K, Srikant CB. Induction of wild-type p53, Bax and acidic endonuclease during somatostatin-signaled apoptosis in MCF-7 human breast cancer cells. Int J Cancer 1998; 76: 259-266.
25. Rohrer SP, et al. Rapid identification of subtype-selective agonists of the somatostatin receptor through combinatorial chemistry. Science 1998; 282: 737-740.
26. Afargan M, et al. Novel long-acting somatostatin analog with endocrine selectivity: potent suppression of growth hormone but not of insulin. Endocrinol 2001; 142: 477-486.
27. Eriksson B, Renstrup J, Imam H, Öberg K. High-dose treatment with lanreotide of patients with advanced neuroendocrine gastrointestinal tumors: clinical and biological effects. Ann Oncol 1997; 8: 1041-1044.